SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

Tresiba

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2015.
Why 3/10
Tresiba is already FDA-approved and commercially marketed with no pending regulatory decision, pivotal readout, or dated binary catalyst in the next ~12 months. It is one product within Novo Nordisk's vast diabetes portfolio (the company's 2025 revenue was DKK 309 billion), and the stock's valuation is overwhelmingly driven by GLP-1 products (Ozempic, Wegovy), not mature insulins. Per the rubric, an approved drug with no upcoming binary scores 3-5; this one lands at 3 because it is a small part of a large, diversified pipeline.
Actionable Insight NEUTRAL

Watch for biosimilar development activity as Tresiba's reference exclusivity approaches expiration around September 2027. Any FDA filing or clinical data from biosimilar developers (e.g., Chinese manufacturers with active programs) could signal future revenue erosion. For Novo Nordisk investors, Tresiba's commercial trajectory is a secondary concern behind the GLP-1 competitive dynamics with Eli Lilly's Mounjaro/Zepbound.

Price Chart

Loading chart...

Executive Summary

Tresiba (insulin degludec) is Novo Nordisk's long-acting basal insulin, FDA-approved in 2015 for type 1 and type 2 diabetes in adults and children as young as 1 year. It offers unique flexible once-daily dosing and a lower risk of nocturnal hypoglycemia versus insulin glargine. The drug is mature and fully commercialized with no upcoming binary catalysts. Novo Nordisk cut US list prices by 72% effective January 2026, reflecting broader insulin pricing pressure. Tresiba faces competition from Lantus, its biosimilars, and other basal insulins, while reference exclusivity is estimated to expire around September 2027. For NVO, a mega-cap pharma company, Tresiba is a small part of a portfolio dominated by GLP-1 obesity and diabetes therapies.

How It Works

Tresiba is a long-acting basal insulin analog. It is a lab-engineered version of human insulin that, when injected under the skin once daily, forms a depot that slowly and steadily releases insulin into the bloodstream for more than 42 hours. This provides consistent blood-sugar control between meals and overnight, with the flexibility to vary the daily injection time as long as at least 8 hours separate doses.

Trial Status

Tresiba was FDA-approved on September 25, 2015, after a two-cycle review. A 2013 Complete Response Letter required a cardiovascular outcomes trial before approval. The pivotal DEVOTE trial (N=7,637) confirmed cardiovascular safety and demonstrated significantly lower rates of severe hypoglycemia compared to insulin glargine. The label has been expanded to include pediatric patients aged 1 year and older. Multiple supplemental approvals and labeling revisions have been issued through 2026 covering post-market surveillance data, pediatric dosing refinements, and updated safety language.

The Two-Sided Case

▲ Bull Case5
Tresiba's ultra-long duration (>42 hours) and flexible once-daily dosing (at least 8 hours between doses) are unique among basal insulins, supporting continued prescribing preference.
The DEVOTE cardiovascular outcomes trial showed a 53% reduction in severe nocturnal hypoglycemia versus insulin glargine, a clinically meaningful differentiator.
No FDA-approved biosimilar for insulin degludec exists as of late 2026, giving Tresiba continued market exclusivity until at least late 2027 (reference exclusivity) or later (patent-protected into 2031).
Tresiba is approved for pediatric patients as young as 1 year, the only basal insulin with that label, providing a niche growth avenue.
The 72% list-price cut effective January 2026 improves formulary access and could offset volume loss from payer steering to cheaper alternatives.
▼ Bear Case5
Tresiba faces intense competition from well-established basal insulins including Lantus (insulin glargine), its interchangeable biosimilars Semglee and Rezvoglar, and Sanofi's Toujeo, all of which exert pricing pressure.
The 72% US list-price cut (effective January 2026) directly reduces per-unit revenue, and Novo Nordisk discontinued unbranded biologic versions of Tresiba, signaling margin compression.
Reference biologic exclusivity is estimated to expire around September 2027, and biosimilar developers (including Chinese manufacturers) have active programs, posing a medium-term erosion risk.
The diabetes market is rapidly shifting toward GLP-1 therapies (Ozempic, Wegovy, Mounjaro), which are Novo Nordisk's primary growth engine; Tresiba is a mature insulin in a commoditizing category.
Novo Nordisk's stock has fallen sharply (52-week range $35.12-$64.16, currently ~$40) amid GLP-1 competitive pressure from Eli Lilly, and Tresiba is too small a contributor to offset that headwind.

Upcoming Catalysts

  • No near-term binary catalysts: Tresiba is a mature, approved product with no pending FDA decision or pivotal trial readout. The 72% US list-price cut took effect January 1, 2026. Reference biologic exclusivity is estimated to expire around September 2027, which could open the door for biosimilar competition, but no biosimilar has been approved as of late 2026.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S 6-K NVO ·Originating report

Sources · 12

Hover a chip for the title
1 drugs.com2 accessdata.fda.gov3 fda.gov4 healthrx.com5 healthrx.com6 fiercepharma.com7 qope.org8 cliffbio.com9 diatribe.org10 healthrx.com11 novonordisk.com12 stockanalysis.com